Iovance Biotherapeutics call volume above normal and …

3 days ago · Bullish option flow detected in Iovance Biotherapeutics (IOVA) with 13,526 calls trading, 1.3x expected, and implied vol increasing over 11 points to 119.35%.

CouponFollow Extension

35%
OFF

Iovance Biotherapeutics Call Volume Above Normal And …

1 week from now

3 days ago · Bullish option flow detected in Iovance Biotherapeutics (IOVA) with 13,526 calls trading, 1.3x expected, and implied vol increasing over 11 points to 119.35%.

businessinsider.com

74%
OFF

Iovance Biotherapeutics Call Volume Above Normal And …

1 week from now

Feb 13, 2024 · Bullish option flow detected in Iovance Biotherapeutics with 5,650 calls trading, 1.2x expected, and implied vol increasing almost 4 points to 201.74%.

tipranks.com

69%
OFF

Iovance Biotherapeutics Call Volume Above Normal And …

1 week from now

Dec 15, 2023 · Bullish option flow detected in Iovance Biotherapeutics with 6,385 calls trading, 1.3x expected, and implied vol increasing over 5 points to 106.69%.

tipranks.com

$58
OFF

Iovance Biotherapeutics Reports Financial Results And Corporate …

1 week from now

Nov 7, 2024 · Iovance Biotherapeutics, Inc. Significant Demand for Amtagvi™ (Lifileucel) Continues with $58.6M in Total 3Q24 Product Revenue Reaffirming Guidance of $160-$165M …

yahoo.com

$32.00
OFF

Iovance Biotherapeutics Poised For Growth: Analyst Reiterates Buy ...

1 week from now

May 10, 2024 · In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Iovance Biotherapeutics (IOVA – Research Report), with a price target of $32.00.

businessinsider.com

$32.00
OFF

Promising Efficacy And Long-term Response Of Iovance …

1 week from now

Nov 5, 2024 · In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Iovance Biotherapeutics (IOVA – Research Report), with a price target of $32.00.

businessinsider.com

FAQs about Iovance Biotherapeutics call volume above normal and … Coupon?

Should you buy iovance Biotherapeutics (Iova – research report)?

Yanan Zhu, an analyst from Wells Fargo, maintained the Buy rating on Iovance Biotherapeutics (IOVA – Research Report). The associated price target remains the same with $25.00. Yanan Zhu has given his Buy rating due to a combination of factors related to the promising results from Iovance Biotherapeutics’ recent trials. ...

Where is iovance Biotherapeutics Inc Iova headquartered?

The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA. View Iovance Biotherapeutics Inc IOVA stock quote prices, financial information, real-time forecasts, and company news from CNN. ...

What is the news sentiment of iovance Biotherapeutics?

Iovance Biotherapeutics has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies. ...

Why did Yanan Zhu buy iovance Biotherapeutics?

Yanan Zhu has given his Buy rating due to a combination of factors related to the promising results from Iovance Biotherapeutics’ recent trials. The company’s study involving lifileucel combined with KEYTRUDA in checkpoint inhibitor-naive metastatic NSCLC patients showed a durable response, particularly in patients with EGFR wild-type tumors. ...

Is iovance a single-drug company?

As we can see below, Iovance is not a single-drug company - besides lifileucel, it is running numerous studies for a second TIL asset, LN-145, in metastatic non-small cell lung cancer ("NSCLC") - the largest oncology market. ...

Why has Joseph pantginis rated iovance Biotherapeutics a buy?

Joseph Pantginis has given his Buy rating due to a combination of factors that suggest a strong potential for Iovance Biotherapeutics’ growth and profitability. The company’s recent earnings report for the first quarter of 2024 surpassed expectations with a lower-than-anticipated loss per share and showed a promising cash position. ...